PTC Therapeutics Announces Impressive Financial Performance and Key Updates for 2025 PTC Therapeutics reported significant financial results for 2025, featuring product revenues of $831 million, boosted by Sephience's successful launch and promising growth.

PTC Therapeutics Announces Impressive Financial Performance and Key Updates for 2025 #USA #PTC_Therapeutics #Warren #Sephience #Evrysdi

PTC Therapeutics Secures Approval for Sephience in Japan to Treat PKU PTC Therapeutics has announced the approval of Sephience™ for treating phenylketonuria (PKU) in Japan, marking a significant milestone for patients and the company.

PTC Therapeutics Secures Approval for Sephience in Japan to Treat PKU #Japan #Tokyo #PTC_Therapeutics #Sephience #Phenylketonuria

PTC Therapeutics Reports Strong Third Quarter 2025 Financial Performance and Sephience Launch PTC Therapeutics announces impressive Q3 2025 results, including robust revenue growth and the successful launch of Sephience, a promising treatment for PKU.

PTC Therapeutics Reports Strong Third Quarter 2025 Financial Performance and Sephience Launch #United_States #revenue_growth #PTC_Therapeutics #Warren,_New_Jersey #Sephience

RareMed Solutions Partners with PTC Therapeutics to Enhance PKU Care with New Services RareMed Solutions is enhancing its relationship with PTC Therapeutics by expanding support services for the newly FDA-approved therapy for PKU, Sephience.

RareMed Solutions Partners with PTC Therapeutics to Enhance PKU Care with New Services #United_States #Pittsburgh #PTC_Therapeutics #Sephience #RareMed_Solutions

PTC Therapeutics Sets the Stage for Growth with Q2 2025 Corporate Update and Financial Performance In their latest corporate update, PTC Therapeutics reveals significant progress with Sephience's launch and robust financial results, marking another promising quarter.

PTC Therapeutics Sets the Stage for Growth with Q2 2025 Corporate Update and Financial Performance #USA #financial_results #PTC_Therapeutics #Warren,_NJ #Sephience

Orsini Partners with PTC Therapeutics to Enhance Care for PKU Patients with SEPHIENCE Orsini, recognized for its dedication to rare disease management, teams up with PTC Therapeutics to support the distribution of SEPHIENCE, a crucial PKU therapy.

Orsini Partners with PTC Therapeutics to Enhance Care for PKU Patients with SEPHIENCE #United_States #Elk_Grove_Village #PTC_Therapeutics #Sephience #Orsini_Pharmacy

Germany will be first launch for PTC's phenylketonuria drug PTC Therapeutics' treatment for the rare disease PKU, Sephience, will launch in its first market next month after getting EU approval.

The #EuropeanCommission has approved #PTCTherapeutics' treatment for the rare disease phenylketonuria (#PKU), #Sephience, setting up a market debut in Germany next month.

pharmaphorum.com/news/germany...

Sephience™ Receives EU Approval for Treating PKU in All Ages PTC Therapeutics announces the European Commission's approval of Sephience™ to treat PKU in all age groups, marking a significant advance in metabolic disorder treatments.

Sephience™ Receives EU Approval for Treating PKU in All Ages #None #PTC_Therapeutics #Sephience #Phenylketonuria

Sephience™ Receives EU Marketing Authorization for PKU Treatment: A Major Leap Forward PTC Therapeutics announces Sephience™ has gained marketing approval from the European Commission to treat phenylketonuria for all ages and severities.

Sephience™ Receives EU Marketing Authorization for PKU Treatment: A Major Leap Forward #None #PTC_Therapeutics #PKU #Sephience

PTC Therapeutics Reports Strong Q1 2025 Financial Performance and Product Updates PTC Therapeutics shares impressive Q1 2025 financial results, showcasing strong revenues and positive developments for its lead product, Sephience.

PTC Therapeutics Reports Strong Q1 2025 Financial Performance and Product Updates #USA #financial_results #PTC_Therapeutics #Warren,_New_Jersey #Sephience

PTC Therapeutics Gears Up for Sephience Launch Following Positive CHMP Opinion for PKU Treatment PTC Therapeutics has received a favorable opinion from the CHMP for Sephience to treat PKU, signaling major advancements in patient care and access across Europe.

PTC Therapeutics Gears Up for Sephience Launch Following Positive CHMP Opinion for PKU Treatment #United_States #PTC_Therapeutics #Warren #Sephience #PKU_Treatment